TNFSF14 and COVID-19: In a phase II clinical trial that tested the effects of a TNFSF14-blocking antibody in 62 patients with mild-to-moderate ARDS due to COVID-19 (13), the group of patients treated with anti-TNFSF14 had significantly decreased respiratory failure and mortality.